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Abstract
Introduction: Very few pragmatic and community-level effectiveness trials integrate the use of qualitative research over all
stages of the trial, to inform trial design, implementation optimization, results interpretation and post-trial policy recommenda-
tions. This is despite the growing demand for mixed methods research from funding agencies and awareness of the vital
importance of qualitative and mixed methods research for understanding trial successes and challenges.
Discussion: We offer examples from work we have been involved in to illustrate how qualitative research conducted within
trials can reveal vital contextual factors that influence implementation and outcomes, can enable an informed adaptation of tri-
als as they are being conducted and can lead to the formulation of theory regarding the social and behavioural pathways of
intervention, while also enabling community engagement in trial design and implementation. These examples are based on pub-
lished findings from qualitative studies embedded within two ongoing large-scale studies demonstrating the population-level
impacts of universal HIV testing and treatment strategies in southern and eastern Africa, and a qualitative study conducted
alongside a clinical trial testing the adaptation, acceptability and experience of short-cycle therapy in children and adolescents
living with HIV.
Conclusions: We advocate for the integration of qualitative with clinical and survey research methods in pragmatic clinical
and community-level trials and implementation studies, and for increasing visibility of qualitative and mixed methods research
in medical journals. Qualitative research from trials ideally should be published along with clinical outcome data, either inte-
grated into the “main” trial papers or published concurrently in the same journal issue. Integration of qualitative research
within trials can help not only to understand the why behind success or failure of interventions in different contexts, but also
inform the adaptation of interventions that can facilitate their success, and lead to new alternative strategies and to policy
changes that may be vital for achieving public health goals, including the end of AIDS.
Keywords: qualitative research; community; randomized controlled trials; publishing; social sciences
Received 9 March 2018; Accepted 20 July 2018
Copyright © 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an
open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
1 | INTRODUCTION
In 2009, Simon Lewin and colleagues published a review on
the use of qualitative methods alongside research trials of
complex healthcare interventions [1]. They observed that of
the 100 trials reviewed (every fifth trial of the 492 trials
listed in the register of the Cochrane Effective Practice and
Organisation of Care Review group for 2001 to 2003), 30
had included qualitative work or had research based on quali-
tative methods associated with them. A number of these trials
had made use of qualitative data before and during the trial,
but only two had, at that time, integrated the use of qualita-
tive research in all stages of the trial. Reasons given for not
using mixed methods included lack of supportive funding and
appropriate qualitative expertise as part of the main research
team. In recent years, the use of mixed methods in trials has
become more accepted by funders [2-5] and social scientists
more likely to be a part of the trial team (not working along-
side the trial) [6-8].
That said, qualitative methods are often still viewed as con-
tributing to particular aspects of the trial such as informing
recruitment of target groups or intervention adherence strate-
gies, measuring and supporting community engagement [9-11]
or contributing to explaining trial results [12-15]. In this com-
mentary, we summarize the key benefits of inclusion of quali-
tative and mixed methods in trials. We examine the use of
qualitative methods for contributing over all stages of the trial,
including trial design, optimizing implementation, interpreting
results and shaping post-trial policy recommendations. We
advocate for equitable collaborative working across disciplines
and in approaches to publication and all forms of dissemina-
tion.
We take several examples, based on published sources,
from work we have been involved in, to illustrate how
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integration of qualitative research within randomized con-
trolled trials and implementation studies can reveal vital con-
textual factors that can influence implementation and
outcomes (including both positive and negative unintended
consequences), can enable an informed adaptation of trials as
they are being conducted and also lead to the formulation of
new hypotheses regarding the social and behavioural path-
ways of intervention action (i.e. theory building). We share
examples of qualitative research studies embedded within two
large community-based trials testing the population-level
effects of universal HIV testing and treatment (UTT) (which
aims to extend HIV counselling and testing to an entire popu-
lation and antiretroviral therapy (ART) to all those person liv-
ing with HIV) in southern and eastern Africa [16], and of a
clinical trial of an intervention to test the adaptation, accept-
ability and experience of short-cycle therapy [17] in children
and adolescents living with HIV.
2 | DISCUSSION
2.1 | A UTT intervention trial in Kenya and Uganda
Our first example is taken from the Sustainable East African
Research in Community Health (SEARCH) (NCT# 01864603)
study, an ongoing community cluster randomized controlled
trial (NCT#01864603) in 32 communities of approximately
10,000 persons each located in three regions in Kenya and
Uganda. SEARCH aims to evaluate the health, economic and
educational impacts of a community-based strategy for immedi-
ate and streamlined ART for all HIV-positive persons. A longitu-
dinal qualitative research study embedded within the trial aims
to reveal social, behavioural and implementation processes that
influence the UTT strategy and its outcomes: why the strategy
works or fails in communities, and how it operates in diverse
settings. The qualitative findings also have been periodically
“fed back” to trial leadership and regional teams to explain how
the intervention has evolved, and to inform optimization. The
SEARCH trial design is adaptive, and newer methods for infer-
ence and estimation of “treatment effect” are used [18], which
permitted refinements to the intervention design and imple-
mentation over time. Thus, inclusion of a longitudinal qualitative
study within SEARCH was particularly valuable. Methods
include annual in-depth interviews with cohorts of community
members, community leaders and healthcare providers, partici-
pant observation at community health campaigns (CHCs) and
focus group discussions with CHC attendees. Data collection
began in February 2014 and is ongoing.
The SEARCH strategy involved multiple interventions to
achieve the UNAIDS 90-90-90 targets. To reach the first
“90%,” the study conducted multi-disease testing and ser-
vices at CHCs combined with home-based testing for those
who did not participate in campaigns [19]. The strategy
began with community ethnographic mapping (used to
define characteristics for pair-matching) as well as consulta-
tive community meetings to ascertain community prefer-
ences for certain intervention elements (non-HIV services,
which varied by community, included hypertension and dia-
betes screening, malaria rapid diagnostic testing, medical
male circumcision, cervical cancer screening and other ser-
vices). To ensure at least 90% of those diagnosed were
linked to care, the study used rapid linkage at testing,
appointment reminders, improved provider access through
telephones and face-to-face meetings, and missed appoint-
ment tracking. To ensure that 90% of those in care have
undetectable viral loads, SEARCH used a “streamlined care”
approach designed to lengthen intervals between visits for
stable patients, offer shorter waiting times and ensure a
friendly environment in clinics [20]. SEARCH demonstrated
the effectiveness of its model for high HIV “cascade cover-
age,” and increased population viral suppression from 45%
to 81%, exceeding the “90-90-90” targets within two years
in intervention communities [21]. Initially, testing uptake in
the study for men was lower than that of women (62% vs.
74%). Early qualitative research findings on the structural
and cultural factors that hindered men’s participation in
testing campaigns [22] helped to explain these observations.
The team found that men’s livelihoods and mobility meant
they were often away from rural homesteads and could not
easily access testing campaigns or HIV care during work
hours. Gender norms that ran counter to men’s care-seek-
ing, and valorized their risk-taking, were also said to inhibit
their interest in CHCs; many men preferred to “test by
proxy,” inferring their own HIV status from their wife’s.
Qualitative interviews and focus groups revealed that health
campaigns and clinics were seen as “female spaces” that
men hesitated to enter, despite incentives and other fea-
tures targeting men. SEARCH responded to these early
observations by adapting its approach to mobilizing men for
testing. The location and timing of CHCs were adjusted to
better meet men’s needs, with more campaigns conducted
near workplaces and on weekends (including “moonlight
CHCs” at Lake Victoria beach landing sites). The resources
allocated for home-based testing (disproportionately pre-
ferred by men) at client-selected locations were increased,
while campaigns were redesigned to include more incen-
tives, sports activities and other features targeting men to
increase their demand for testing. These included football
matches, boat races and live bands at campaigns. Men’s
“spaces” and services were set up at campaigns, including a
“men’s tent” offering counselling on male sexuality, urgent
care services and linkage to male circumcision. Local formal
and informal male community leaders were hired to assist
with mobilizing other men.
These efforts yielded positive results vis-a-vis community-
wide participation in testing, and also in qualitative findings
showed that they precipitated new opportunities and anxieties
related to the disclosure of HIV-positive status among those
either newly diagnosed or confronted anew with a need to
disclose as a result of the intervention. An analysis of experi-
ences related to disclosure of HIV status in narratives of peo-
ple living with HIV (PLHIV) from SEARCH published by Maeri
and colleagues [23] revealed that HIV-related stigma in com-
munities during the study’s baseline year was perceived to be
high by community members. Many individuals resisted disclo-
sure because of anticipated stigma, and there were stark gen-
der inequities in the negative consequences of disclosure, with
women more likely than men to experience violence or aban-
donment by partners as a result of their disclosure of HIV-
positive status. That analysis called for efforts to strengthen
capacity in health systems for gender-sensitive provider-
assisted disclosure to address the differing support needs of
men and women.
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2.2 | A trial testing a health system intervention to
accelerate ART initiation in Uganda
At the same time, qualitative research in SEARCH using data
collected in the first two years of the study provided early
signs that norms, beliefs and attitudes related to HIV testing,
status disclosure and engaging in HIV treatment were chang-
ing. Combining these with data collected from another large
randomized controlled trial, the Streamlined ART Initiation
Strategy (START-ART) trial in Uganda (NCT#01810289), an
analysis published in this journal by Camlin and colleagues
[24] posited an unforeseen pathway of intervention action in
strategies that seek to harness the potential of ART to bring
about improvements in individual health outcomes for PLHIV
and large-scale reductions in HIV incidence. In that article,
authors propose that the advent of widespread testing cam-
paigns and efforts to accelerate antiretroviral “treatment for
all” in eastern African communities has precipitated a rapidly
expanding shift in how people living with HIV infection view
themselves and act in the community to promote better
health for other PLHIV. HIV-related stigma acts to reinforce
hierarchies of power and to systemically exclude those less
enfranchised from society and render them “invisible.” But nar-
ratives from PLHIV in communities and in clinics revealed that
whether or not they were remunerated, and whether they
encountered other PLHIV in clinics or in communities, PLHIV
in Kenya and Uganda have been taking on new roles and self-
conceptualizations that are transforming their “spoiled” or stig-
matized identity into a new valorized social identity, finding a
moral “redemption” via their public advocacy of HIV testing
and treatment. These trials did not foresee or plan for it; but
as the benefits of ART embolden more and more PLHIV to
openly engage in care, many “advocates for ART” are emerging
in communities, actively engaged in encouraging others to
test, to enrol in HIV treatment, to adhere to ART regimens
and to stay engaged in care. PLHIV are not only creating a
renewed, destigmatized subjecthood, but are leading opinions
and playing a pivotal role in shaping new social norms and
attitudes related to HIV testing and treatment in eastern
Africa. These findings have led to a deeper understanding of
the community impact of the UTT strategy and presented
opportunities to engage and support the unanticipated posi-
tive social change.
2.3 | A UTT intervention trial in Zambia and South
Africa
Our next example also illustrates the value of qualitative
research for informing trial teams about study communities in
the early stages of a trial and for shaping subsequent
research. Social science research is integrated into the design
of HPTN 017 (Population Effects of Antiretroviral Treatment
to Reduce HIV Transmission [PopART]) cluster randomized
trial [25] to demonstrate the effects of a UTT strategy, as is
the case with SEARCH. In 2013, during the initial selection of
the 21 communities in Zambia and South Africa for HPTN
071, rapid qualitative research (termed a Broad Brush Survey
[26]) was conducted to gather data on each community, prior
to the implementation of the trial intervention. While the
results of this work are drawn on in a number of publications
[27-30], this example focuses on the work published by Bond
and colleagues in 2016 [31]. For the rapid assessment, a small
team of social science researchers spent about two weeks
staying in each study community to undertake data collection,
using group discussions, key informant interviews and obser-
vations. The work was organized in a sequence to ensure the
team acquired a good overview of the setting before holding
in-depth interviews and discussions about the “HIV landscape”
of the community, including access to HIV prevention and care
services. Those data were used to document the social, demo-
graphic and economic profile of each site for use by the trial
implementation team, and also to conduct analysis of the con-
textual heterogeneity across sites. The authors analysed the
variability in response to HIV interventions early in the trial
using first year process indicator data from the trial (2014 to
2015) from four Zambian intervention communities (“Arm A”)
along with the qualitative assessment findings [31]. The latter
data were organized according to four meta-indicators span-
ning physical features, social organization, social networks and
“community identity” narratives, to facilitate comparison
between communities. These indicators were developed by a
research group aiming to classify the “capability” of response
to change across diverse settings in Rome, Turin, London,
Zambia and South Africa [32]. Applying the meta-indicator
frame to the HPTN 071 rapid assessment data, Bond and col-
leagues concluded that combining the two sets of data pro-
vided valuable insights regarding which differences between
communities were likely to matter for HIV intervention
uptake. For example, “social organization” differences that mat-
tered included mobility (primarily for work), young men’s work
patterns, population variability across different housing types
and the presence of HIV stakeholders. These were factors
that could be tracked for change over the duration of the trial
and be used to help interpret variability in the trial outcomes
[29].
2.4 | A multi-country trial to develop a treatment
intervention for young people living with HIV
The last example is from the BREATHER (PENTA 16) clinical
trial. Working across 11 countries (including one centre in
Uganda), this trial compared virological control of short-cycle
therapy (five days on: two days off) with continuous EFV-
based ART in 199 children and young people (aged 8 to 24)
(70 from Uganda) living with HIV with viral load <50 c/mL
to examine adaptation, acceptability and experience of short-
cycle therapy to inform intervention development [17,33].
The social science component was not fully funded within
the trial funding, and a parallel grant from a different funder
was secured by the social scientists to support the qualita-
tive research in Uganda. The qualitative study consisted of
repeat in-depth interviews with a sample of participants from
both arms of the trial, and discussion groups at the end to
discuss emerging trial results. The qualitative data showed
that while there was a strong preference for the option of
short-cycle therapy, to allow weekends off from treatment,
young people from both arms reported frequent medication
side effects and occasional missed doses that they had rarely
shared with clinical staff [34]. The final discussion group
allowed participants to voice concerns about the risks of
short-cycle therapy for young people who struggled to
adhere to treatment [35]. These findings informed the way
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in which the final trial findings were reported and could pro-
vide valuable input for further research. It should be noted
that while some of the qualitative study findings were inte-
grated into the “main” trial paper the paper [17] detailing
the qualitative findings (which was submitted at the same
time as the main trial findings paper) was not accepted for
publication. The qualitative findings paper was published later
in a different journal [34].
3 | CONCLUSIONS
With increased attention to translating biomedical research
advances into clinical practice, policy and population-level
impact (requiring widespread social and behavioural change),
there is a demand for incorporation of qualitative methods in
pragmatic clinical and community-level trials and implementa-
tion science studies [4]. The structure of this methods “mix-
ture” can draw upon existing taxonomies of mixed methods
designs [36,37], but we suggest that the integration of quali-
tative methods within trials, particularly when applied using
constructivist grounded theoretical approaches (e.g. as articu-
lated by Charmaz [38]), can allow researchers to not only
pursue a set of research questions defined a priori, but also
generate new avenues of inquiry and opportunities for theory
building in response to unexpected empirical findings. Espe-
cially in complex trials, interventions are often not imple-
mented as planned, secular trends affect outcomes, and
outcomes and their generalizability cannot be interpreted
intelligibly without an in-depth understanding of context. The
increasing use of novel adaptive trial designs and hybrid
implementation-effectiveness trial designs is propitious for
integration of longitudinal qualitative research, because these
designs facilitate use of qualitative findings to inform opti-
mization of interventions as they are being implemented;
moreover, these designs value measurement of heteroge-
neous “implementation” and “contexts,” aiming to elucidate
rather than obscure these factors. The integration of qualita-
tive research within trials can help not only to understand the
why behind success or failure of interventions in different
contexts, but also inform the adaptation of interventions that
can facilitate their success, and lead to new alternative strate-
gies and to policy changes that may be vital for achieving
public health goals.
We advocate specifically for the pairing of qualitative with
clinical and survey research methods in trials and implementa-
tion studies, and for the publication of qualitative research
from trials with clinical outcome data, either fully integrated
into the “main” trial papers or published concurrently in the
same journal issue. The option of two complementary papers
(of equal weight) is probably the most viable, given word limits
may preclude adequate coverage of all results in one paper.
The findings from qualitative research within trials offer
valuable information on the ways people behave and commu-
nicate, and the complex social worlds with which research is
conducted – information that is essential to the understanding
of trials’ results [6]. However, we continue to find that papers
based on qualitative methods from trials are afforded lower
priority by many medical journals, despite recent efforts to
urge editors to reconsider policies towards the publication of
such research [39]. Social scientists continue to push the
boundaries of disciplinary biases in biomedical HIV research
and the medical literature, but the advocacy of clinical
researchers is essential to achieve widespread awareness that
biomedical research is strengthened through the inclusion of
social sciences in the centre of its sphere of inquiry.
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